



# FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP  
600 CONGRESS AVENUE, SUITE 2400  
AUSTIN, TEXAS 78701-3271  
[WWW.FULBRIGHT.COM](http://WWW.FULBRIGHT.COM)

GSHISHIMA@FULBRIGHT.COM  
DIRECT DIAL: (512) 536-3081

TELEPHONE: (512) 474-5201  
FACSIMILE: (512) 536-4598

COPY OF PAPERS  
ORIGINALLY FILED

May 24, 2002

## CERTIFICATE OF MAILING 37 C.F.R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:

May 24, 2002

Date

Gina N. Shishima

Commissioner for Patents  
Washington, DC 20231

RE: SN 09/841,720 "MU OPIOID RECEPTOR METHODS (as amended)" - by Yu

Commissioner:

Enclosed for filing in the above-referenced patent application is:

- (1) Response to Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence Disclosures;
- (2) Statement as Required Under 37 C.F.R. §1.85(a) and (b) and as Required Under 37 C.F.R. §1.821(g) (with paper copy and computer readable copy of sequence listing); and
- (3) A return postcard to acknowledge receipt of these materials. Please date stamp and mail this postcard.

Should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed materials, the Commissioner is authorized to deduct said fees from Fulbright & Jaworski L.L.P. Account No.: 50-1212/10103856/GNS.

Respectfully submitted,

Gina N. Shishima  
Reg. No. 45,104

:lb

Encl.: As stated

25121015.1



COPY OF PAPERS  
ORIGINALLY FILED

CERTIFICATE OF MAILING 37 C.F.R 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on the date below:	
May 24, 2002 Date	Gina N. Shishima

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Yu

Serial No.: 09/841,720

Filed: April 24, 2001

For: MU OPIOID RECEPTOR METHODS (as  
amended)

Group Art Unit: 1647

Examiner: Unknown

Atty. Dkt. No.: INDA:002USD1

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS  
FOR PATENT APPLICATIONS CONTAINING  
NUCLEOTIDE SEQUENCE DISCLOSURES**

**BOX SEQUENCE**


Commissioner for Patents  
Washington, DC 20231

Commissioner:

This paper is submitted in response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence Disclosures mailed March 27, 2002, for which the two month date for response is May 27, 2002. A Statement as Required Under 37 C.F.R. § 1.825(a) and (b) and Statement as Required Under 37 C.F.R. § 1.821(g) has been included herewith, including a computer readable form.

It is believed that no fee is due. However, should any fees be due for any reason related to these documents, the Commissioner is authorized to withdraw the appropriate fee under 37 C.F.R. §§ 1.16 to 1.21 from Fulbright & Jaworski L.L.P. Account No.: 50-1212/10103856/GNS.

Respectfully submitted,



Gina N. Shishima  
Reg. No. 45,104  
Attorney for Applicant

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 474-5201  
(512) 536-4598 (facsimile)

Date: May 24, 2002